Rivastigmine tartrate (Exelon) is a medication developed and marketed by Novartis for the treatment of Alzheimer's disease and Dementia with Lewy bodies. The drug inhibits cholinesterase and butyrylcholinesterase and is designed for symptomatic treatment of early- to middle-stage Alzheimer's.

See also

• "Acetylcholinesterase inhibitors" section of the "Alzheimer's disease" article

Antidementia agents | Pharmacologic agents | Novartis

Rivastigmin | Rivastigmin